ophthalmology

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

News

Pathogenic Acanthamoeba as seen under a light microscope

EU approves first therapy for acanthamoeba keratitis

The European Commission has approved SIFI's Akantior as the first therapy anywhere in the world for acanthamoeba keratitis (AK), an ultra-rare parasitic infection that can lead to blindness

News

Roche will relaunch AMD implant Susvimo after update

Roche’s Genentech unit has said will reintroduce its Susvimo implant for eyesight-robbing disease age-related macular degeneration (AMD), which was withdrawn from sale in 2022 due to manufa

News

Update: MSD confirms $3bn takeover of EyeBio

MSD has confirmed a $3 billion takeover deal for ophthalmology biotech EyeBio and its drug candidate for diabetic macular oedema (DME) and neovascular age-related macular

News

eyeDNA plans pivotal trial of retinitis pigmentosa therapy

Two-year data with eyeDNA Therapeutics’ gene therapy for retinitis pigmentosa (RP), an inherited form of blindness, has prompted the biotech to seek discussions with regul

News

Boehringer raises hope of diabetic macular ischaemia therapy

Boehringer Ingelheim says it may have found the first therapy for diabetic macular ischaemia (DMI), a common and irreversible complication of the eye in people with diabet

Viridian takes aim at Amgen's Tepezza with veligrotug data

EU approves first therapy for acanthamoeba keratitis

Roche will relaunch AMD implant Susvimo after update

Update: MSD confirms $3bn takeover of EyeBio

eyeDNA plans pivotal trial of retinitis pigmentosa therapy

Boehringer raises hope of diabetic macular ischaemia therapy

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

ophthalmology

Editor's Picks